Breaking News, Promotions & Moves

Antag Therapeutics Adds New Leadership

Welcomes three new hires with deep expertise that will be instrumental as Antag progresses its GIPR antagonist AT-7687 through the clinic.

Author Image

By: Charlie Sternberg

Associate Editor

Antag Therapeutics, a biopharmaceutical company pioneering novel treatments for obesity, has appointed three new hires to support the Company’s next phase of growth following the recent initiation of a Phase 1 trial of its GIP receptor antagonist AT-7687. Dr. Jens Chr. Norrild joins as Vice President, Head of Chemistry, Manufacturing and Controls (CMC); Dr. Ayna Baladi Nejad as Director of Clinical Pharmacology; and Dr. Imke Tiessen as Chief of Staff. Jörg Möller, who was appointed CEO of ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters